Evaluating New Data for Transplant-Eligible Patients With NDMM: PERSEUS, IsKia, and GMMG HD7

Author(s):

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA,Amir Ali, PharmD, BCOP

Key Takeaways

Phase 3 trials PERSEUS, IsKia, and GMMG HD7 compare triplet and quadruplet regimens in transplant-eligible multiple myeloma patients.
CD38 antibodies are being integrated into treatment protocols, showing improved outcomes with quadruplet regimens.
Enhanced response rates and progression-free survival are observed with the inclusion of CD38 antibodies in upfront treatment.
Oncologists are adapting treatment strategies based on these pivotal trial findings to optimize patient outcomes.

Panelists discuss how recent phase 3 trial data from PERSEUS, IsKia, and GMMG HD7 are shaping their approach to induction and consolidation therapy in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients, particularly focusing on the incorporation of CD38 antibodies into upfront treatment regimens and the potential shift from triplet to quadruplet therapies based on these pivotal trial findings.

EP: 1.Treatment Landscape for Transplant-Eligible Patients with NDMM

EP: 2.Frontline Treatment and Sequencing Therapy

EP: 3.Impact of Transplant Eligibility on Treatment Selection

EP: 4.Treatment Regimen Considerations

EP: 5.Impact of IFM 2009 and DETERMINATION Studies

EP: 6.Key End Points in Clinical Trials

EP: 7.Real-World Considerations for New Therapies

EP: 8.Challenges in Adopting Novel Therapies

Now Viewing

EP: 9.Evaluating New Data for Transplant-Eligible Patients With NDMM: PERSEUS, IsKia, and GMMG HD7

EP: 10.Impact of SC Daratumumab

EP: 11.SC vs IV Administration Methods

EP: 12.Pharmacists’ Roles in MM Management

EP: 13.Pharmacists’ Roles on the Multidisciplinary Team

EP: 14.Personalizing Treatments and Patient Education

EP: 15.Addressing Payer Coverage Challenges

EP: 16.Unmet Needs for Transplant-Eligible NDMM

Video content above is prompted by the following:

What are your thoughts on the following phase 3 trial data on induction and consolidation therapy in transplant-eligible patients with newly diagnosed multiple myeloma (ie, triplet vs quadruplet regimens)?
PERSEUS
IsKia
GMMG HD7
(Dr Ali) How are you incorporating recent pivotal trial findings around CD38 antibodies into upfront treatment decisions for transplant-eligible populations (ie, PERSEUS, IsKia, and GMMG HD7)?